Trethera
  • Home
  • About Us
  • Technology
  • Pipeline
  • Media
    • News
    • Publications
  • Contact
  • Menu

News


Dose Escalation Portion of Phase 1 Solid Tumors Trial Produces Favorable Results in Heavily Pretreated Solid Tumor Patients


Trethera Announces Appointment of Laurent Dubois to Board of Directors


Trethera Announces Poster Presentation at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Meeting


Trethera Announces Appointment of R. Boyd Quinnell to Board of Directors


Trethera Receives $1.6 Million National Eye Institute Grant for Continued Advancement of TRE-515 Optic Neuritis Program


Trethera Announces Multiple Sclerosis Treatment Poster Presentation at the American Neurological Association Annual Meeting


U.S. Patent Office Issues Trethera Composition of Matter Patent Covering TRE-515, Extending Market Exclusivity to Late 2041


Trethera and UCLA Publish Data Demonstrating TRE-515 Ability to Control and Improve Multiple Sclerosis Symptoms in Mouse Models


Trethera Receives U.S. Patent Office Notice of Allowance Covering TRE-515 Structural Claims, Extending Protections to Late 2041


Trethera Phase 1 Solid Tumors Trial Dose Escalates To Fourth Cohort After Safety Review Committee Determines Primary Trial Endpoint Achieved


Trethera Scientific Founder Dr. Caius Radu To Present Research At Los Angeles Bioscience Ecosystem Summit 2022


Trethera Announces Completion of $3.8 Million Seed Funding Round From Current Investors


Trethera Announces Prostate Cancer Poster Presentation at the American Association for Cancer Research Annual Meeting


Safety Review Committee Advances Trethera Phase 1 Solid Tumors Trial to Next Dose After First Patient Cohort Achieves Primary Endpoint


Trethera Announces FDA Orphan Drug Designation Granted to TRE-515 for the Treatment of Demyelinating Optic Neuritis


Trethera Doses First Patient in Landmark Clinical Trial for the Treatment of Solid Tumors With First-In-Class Drug TRE-515


Globally Recognized Multiple Sclerosis Expert, Dr. Lawrence “Larry” Steinman, Joins Trethera Scientific Advisory Board


Trethera Receives FDA Approval To Initiate TRE-515 Phase 1 Clinical Trial in Solid Tumors Monotherapy


Trethera Announces Jefferies & Company Chairman Emeritus Frank Baxter as Special Advisor


Trethera Announces Completion of $3.2 Million Seed Funding Round From Current Investors


Trethera Announces FDA Orphan Drug Designation Granted to TRE-515 in the Treatment of Acute Disseminated Encephalomyelitis


View All

Publications


ATR inhibition facilitates targeting of leukemia dependence on convergent nucleotide biosynthetic pathways


Co-targeting of convergent nucleotide biosynthetic pathways for leukemia eradication


Nucleoside salvage pathway kinases regulate hematopoiesis by linking nucleotide metabolism with replication stress.


View All